Attached files
| file | filename |
|---|---|
| EX-99.2 - INVESTOR PRESENTATION PDF - CHEMBIO DIAGNOSTICS, INC. | investorpresentation.pdf |
| EX-99.3 - FACT SHEET PDF - CHEMBIO DIAGNOSTICS, INC. | factsheet.pdf |
| 8-K - FORM 8-K FOR PR OF 5-6-10 - CHEMBIO DIAGNOSTICS, INC. | form8_k.htm |
| EX-99.2 - INVESTOR PRESENTATION WORD - CHEMBIO DIAGNOSTICS, INC. | ex99_2.htm |
| EX-99.1 - PRESS RELEASE OF 5-6-10 - CHEMBIO DIAGNOSTICS, INC. | ex99_1.htm |
(See PDF)
PAGE 1
Investor Fact Sheet
Ticker Symbol: CEMI
www.chembio.com
Business Summary & Investment Highlights
Chembio Diagnostics, Inc. (Chembio), through its wholly owned subsidiary Chembio Diagnostic Systems, Inc., develops, manufactures, licenses and markets point-of-care testing (POCT) products. Chembio created and patented a new revolutionary technology called Dual Path Platform (DPP®). The technology is addressing critical market requirements in the infectious diseases testing market and other growing markets. Products under development, both OEM and branded, are anticipated to create
significant new revenue streams that will add to Chembio’s core business of rapid HIV tests.
• >30% Five Year Revenue CAGR.
• 148% YOY sales increases of Chembio’s FDA approved lateral flow HIV tests that are marketed in the U.S. by Inverness Medical Innovations, Inc. (IMA:NYSE), a leading POCT company. IMA markets Chembio’s products as Clearview® COMPLETE HIV 1/2 globally and Clearview® HIV 1/2 STAT-PAK® in the U.S. to hospital emergency departments, public health clinics, and physicians offices.
• Robust pipeline of POCT products for HIV (oral fluid), Syphilis, Influenza, Hepatitis-C (oral fluid), and other infectious diseases based on Chembio’s patented DPP® technology. Major benefits include improved sensitivity, multiplexing, sample control and quantitative measurements.
• Point-of-care testing is the fastest growing segment of the $40 billion in-vitro diagnostic market. Drive for cost containment and need for quick results have caused the market to grow rapidly.
Selected Financial Information
Stock Information
Ticker Symbol CEMI
Price 4/30/10 $0.23
52 Week High $0.39
52 Week Low $0.10
Outstanding Shares (MM) 62.0
Market Capitalization (MM) $14.26
Fully Diluted (FD) Shares 70.7
Management Holding-FD 11.2
Average Volume (3 Mos) 130,000
Major Beneficial Holders Beneficial Shares Owned (MM)
Lawrence Siebert 6.9
Inverness Medical Innovations, Inc. 5.4
Crestview Capital Offshore Fund, Inc. 3.4
|
Balance Sheet Data ($000s)
|
Mar.’10
|
Dec. '09
|
|
Cash
|
$798
|
$ 1,068
|
|
Accts. Receivable
|
1,178
|
1,776
|
|
Inventories
|
1,980
|
1,556
|
|
Other Current Assets
|
285
|
267
|
|
Total Current Assets
|
4,241
|
4,667
|
|
Net Fixed Assets
|
850
|
580
|
|
Other Assets
|
773
|
1,068
|
|
Total Assets
|
5,864
|
6,315
|
|
Total Current Liab.
|
2,810
|
3,173
|
|
Total Other Liab.
|
46
|
54
|
|
Total Liabilities
|
2,856
|
3,227
|
|
Total Equity
|
3,008
|
3,088
|
|
Total Liabilities & Shareholders Equity
|
$5,864
|
$ 6,315
|
|
Selected Comparative Historical Financial Data
|
|||||||
|
Quarter Ended Year Ended
|
Three Mos Ended
|
For the Years Ended
|
|||||
|
$(000s)
|
Mar.31, 2010
|
Mar. 31, 2009
|
2009
|
2008
|
2007
|
2006
|
2005
|
|
Total Revenues
|
$ 2,783
|
$ 2 ,546
|
$13,834
|
$11,050
|
$9,231
|
$6,503
|
$3,941
|
|
Cost of sales
|
1,477
|
1,547
|
7,974
|
7,198
|
6,435
|
4,894
|
2,996
|
|
Gross Profit
|
1,306
|
999
|
5,860
|
3,852
|
2,796
|
1,609
|
945
|
|
46.9%
|
39.2%
|
42.4%
|
34.9%
|
30.3%
|
24.7%
|
24.0%
|
|
|
R&D Expense
|
801
|
647
|
2,884
|
2,605
|
1,907
|
1,402
|
1,365
|
|
SG&A Expense
|
661
|
676
|
2,659
|
3,317
|
3,765
|
4,787
|
2,878
|
|
Operating Income (Loss)
|
(156)
|
(324)
|
317
|
(2,071)
|
(2,876)
|
(4,580)
|
(3,298)
|
|
Other Inc. (Expense)
|
(1)
|
(1)
|
(8)
|
122
|
249
|
(415)
|
46
|
|
Net Income (Loss) - Stkhldrs
|
(157)
|
(325)
|
309
|
(1,949)
|
(2,627)
|
(4,995)
|
(3,252)
|
|
Pref. Stock Expenses
|
-
|
-
|
-
|
-
|
5,645
|
3,210
|
3,517
|
|
Net Loss
|
($157)
|
($325)
|
$ 309
|
$ (1,949)
|
$ (8,272)
|
$(8,205)
|
$(6,769)
|
|
Net Income (Loss) - per Share
|
$ 0.00
|
$ (0.01)
|
$ 0.00
|
$ (0.03)
|
$ (0.57)
|
$ (0.80)
|
$(0.88)
|
|
Avg. No. Shares (Millions)
|
61.986
|
61.945
|
61.946
|
61.267
|
14.608
|
10.293
|
7.705
|
|
Working capital
|
1,431
|
$1,334
|
$1,494
|
$1,664
|
$3,229
|
$5,113
|
$831
|
|
Total assets
|
5,864
|
5,697
|
6,315
|
5,915
|
6,585
|
7,907
|
3,016
|
|
Total liabilities
|
2,856
|
3,429
|
3,227
|
3,338
|
2,322
|
2,297
|
1,964
|
|
Equity (Deficit)
|
3,008
|
2,268
|
3,088
|
2,577
|
4,263
|
(940)
|
1,053
|
Chembio Diagnostics, Inc.
3661 Horseblock Road
Medford, NY 11763
Ph. 631-924-1135
Fax 631-924-2065
www.chembio.com
Investor Relations
The Investor Relations Group
James Carbonara, JCarbonara@investorrelationsgroup.com
212-825-3210
Company Contact
Susan Norcott, Snorcott@chembio.com
631-924-1135 x125
PAGE 2 –
Chembio’s Lateral Flow Rapid HIV Tests Marketed Exclusively in the USA by Inverness Medical Innovations, Inc.
DPP® Technology
Competitive Advantages For POC Testing
• Improved Sensitivity - enabled by more efficient binding method
• Easier Multiplexing - due to even and direct distribution of sample to multiple test lines
• Enhanced Sample Control - as result of independent sample migration path
• Clearer Results - efficient binding allows for improved functionality of instruments for reading and reporting of qualitative or quantitative results
Chembio’s Dual Path Platform (DPP®) Patented in 2007
Senior Management Team
Lawrence A. Siebert, Chairman & CEO, 25 years of management and financing experience
Richard J. Larkin, CFO, 25 years of operational and financial experience
Javan Esfandiari, SVP R&D, 15 years of experience in development of in-vitro point of care products
Board of Directors
Katherine Davis - Former Lieutenant Governor and numerous other leadership positions for the State of Indiana; former senior executive of Cummins, INC. (NYSE:CMI)
Dr. Gary Meller - Broad experience in medical and information technology and pharmaceutical product development
Except for the historical information contained herein, the matters discussed in this document are forward-looking statements, the accuracy of which is subject to risks and uncertainties. Please refer to Chembio Diagnostics, Inc.'s most recent Form 10-K and Forms 10-Q for additional information about the Company andrelated risks. - May 2010